Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year earnings per share growth rate
| Period | Value |
|---|---|
| Q3 2025 | -14.06% |
| Q2 2025 | -53.60% |
| Q1 2025 | -109.00% |
| Q4 2024 | 390.81% |
| Q3 2024 | -97.03% |
| Q2 2024 | 167.46% |
| Q1 2024 | -1285.08% |
| Q4 2023 | 62.02% |
| Q3 2023 | 80.94% |
| Q2 2023 | 30.95% |
| Q1 2023 | 18.47% |
| Q4 2022 | -407.19% |
| Q3 2022 | 124.55% |
| Q2 2022 | 41.11% |
| Q1 2022 | -16.23% |
| Q4 2021 | 2.83% |
| Q3 2021 | -9.91% |
| Q2 2021 | 51.30% |
| Q1 2021 | -68.03% |
| Q4 2020 | -16.10% |
| Q3 2020 | 13.76% |
| Q2 2020 | 43.36% |
| Q1 2020 | -1323.66% |
| Q4 2019 | 139.73% |
| Q3 2019 | 35.96% |
| Q2 2019 | 18.73% |
| Q1 2019 | 16.39% |
| Q4 2018 | 77.41% |
| Q3 2018 | -281.13% |
| Q2 2018 | -50.27% |
| Q1 2018 | -6322.30% |
| Q4 2017 | -116.51% |
| Q3 2017 | 2165.64% |
| Q2 2017 | 29.13% |
| Q1 2017 | -8.49% |
| Q4 2016 | 74.91% |
| Q3 2016 | -72.80% |
| Q2 2016 | 31.42% |
| Q1 2016 | -12.46% |
| Q4 2015 | -560.42% |